In a female patient with progressive insomnia after initiating estrogen therapy, a history of Chiari malformation, normal polysomnography respiratory indices but a high spontaneous arousal index, and prior limited response to hypnotics, what is the recommended management?

Management Recommendation for Progressive Insomnia with High Arousal Index

This patient requires cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, with careful evaluation of the temporal relationship between estrogen therapy initiation and insomnia onset, and consideration of her Chiari malformation as a potential contributor to sleep fragmentation. 1, 2

Primary Diagnosis and Key Findings

This patient presents with chronic insomnia disorder characterized by:

• Severe sleep onset insomnia (hours to fall asleep vs. previous 7:30 PM onset)
• Sleep maintenance difficulties with frequent awakenings
• Markedly elevated spontaneous arousal index of 23.2/hour (normal <15/hour)
• Total arousal index of 24.6/hour
• Normal respiratory parameters (AHI 0.3/hr, ruling out OSA)
• Temporal correlation with estrogen therapy initiation one month ago
• Background Chiari malformation

The PSG objectively confirms insomnia with reduced sleep efficiency (87.5%), decreased REM sleep (14.5%), and most critically, excessive spontaneous arousals indicating hyperarousal state—the hallmark of psychophysiologic insomnia.

Treatment Algorithm

Step 1: Initiate CBT-I as Primary Treatment

CBT-I is the mandatory first-line intervention for chronic insomnia disorder 1, 2. This is a strong recommendation based on moderate-quality evidence showing superior long-term outcomes compared to pharmacotherapy alone.

Specific CBT-I components to implement:

• Stimulus control therapy: Eliminate the 6:30 PM bedroom entry; restrict bedroom use to sleep and sex only; leave bed if unable to sleep within 20 minutes
• Sleep restriction therapy: Calculate current sleep efficiency (413 minutes asleep ÷ 472 minutes in bed = 87.5%); initially restrict time in bed to match actual sleep time plus 30 minutes, then gradually expand as efficiency improves to >90%
• Cognitive therapy: Address maladaptive beliefs about sleep, particularly given her Epworth score of 0 suggesting minimal daytime sleepiness despite severe insomnia complaints
• Relaxation training: Target the elevated arousal state evidenced by the 23.2 spontaneous arousals/hour

CBT-I can be delivered via in-person sessions, telehealth, or Internet-based platforms—all show efficacy 3. The patient should receive 4-8 sessions over 6-10 weeks 4.

Step 2: Address Potential Hormonal Contribution

Coordinate with her gynecologist regarding estrogen therapy timing. The insomnia onset coinciding with estrogen initiation one month ago is clinically significant. While evidence shows hormone therapy may improve subjective sleep quality in late menopausal transition 5, individual responses vary. Consider:

• Do not discontinue estrogen abruptly without gynecologic consultation
• Monitor whether CBT-I alone improves symptoms while continuing current hormone regimen
• If insomnia persists after 8 weeks of CBT-I, discuss with gynecologist whether estrogen formulation, dose, or timing adjustments might be warranted
• Note that objective sleep improvements with hormone therapy show inconsistent results after statistical adjustment 5

Step 3: Evaluate Chiari Malformation Contribution

Consult with her neurologist regarding the Chiari malformation's potential role in sleep fragmentation. While her respiratory parameters are normal (ruling out central sleep apnea commonly seen in Chiari), the elevated spontaneous arousal index warrants consideration of:

• Whether brainstem compression could contribute to arousal mechanisms 6, 7
• The relationship between her morning headaches and sleep fragmentation
• Whether her Chiari imaging findings (degree of tonsillar descent) correlate with arousal frequency
• Chiari can cause central breathing disorders in 34% of pediatric cases 6, though less commonly in adults with isolated insomnia

However, the normal AHI and absence of central apneas make Chiari an unlikely primary driver of her current insomnia presentation.

Step 4: Optimize Current Pharmacotherapy During CBT-I

Continue Ambien 7.5 mg PRN while initiating CBT-I, but with specific guidance 4:

• Use intermittently (3 nights per week maximum) rather than nightly to prevent tolerance
• Time administration strategically on nights when sleep restriction is most challenging
• Plan for gradual taper as CBT-I skills develop (typically after 4-6 weeks)
• Medication discontinuation is facilitated by concurrent CBT-I 4

Do not retry previously failed medications (doxepin, trazodone, quetiapine) given her documented poor response and morning grogginess 4.

Step 5: If CBT-I Alone Fails After 8-10 Weeks

Reassess for occult comorbid disorders 4:

• Re-evaluate depression/anxiety (given elevated cognitive arousal)
• Consider paradoxical insomnia component (given discrepancy between PSG showing 413 minutes sleep vs. her report of "inability to fall asleep at all") 8
• Assess for conditioned arousal given the maladaptive sleep behaviors (entering bedroom at 6:30 PM, prolonged time in bed while awake)

If pharmacotherapy augmentation is needed after failed CBT-I, use shared decision-making 1 and consider:

• First choice: Alternative short-acting benzodiazepine receptor agonist (eszopiclone or zaleplon) given partial Ambien response 4
• Second choice: Ramelteon (targets circadian component without morning grogginess she experienced with sedating antidepressants)
• Avoid: Sedating antidepressants given her documented poor tolerance and lack of comorbid depression/anxiety

Critical Pitfalls to Avoid

1. Do not continue PRN Ambien indefinitely without CBT-I—pharmacotherapy alone has inferior long-term outcomes and higher relapse rates 4, 1

2. Do not dismiss the elevated arousal index—this objective finding confirms hyperarousal pathophysiology requiring behavioral intervention, not just medication escalation

3. Do not overlook sleep hygiene violations: Her 6:30 PM bedroom entry and prolonged time in bed while awake are perpetuating conditioned arousal 4

4. Do not attribute all symptoms to Chiari without evidence—her normal respiratory parameters make Chiari-related sleep-disordered breathing unlikely as the primary cause

5. Do not ignore the estrogen timing—this temporal relationship requires gynecologic collaboration, though hormone adjustment should not delay CBT-I initiation

Follow-Up Schedule

• Every 2-4 weeks initially during active CBT-I treatment 4
• Collect sleep diary data continuously 4
• Reassess with Insomnia Severity Index at 4,8, and 12 weeks
• Every 6 months long-term given high insomnia relapse rates 4
• Consider repeat PSG only if new symptoms emerge suggesting sleep-disordered breathing or if Chiari-related concerns develop

The combination of CBT-I with strategic, intermittent hypnotic use offers the best evidence-based approach for this patient's severe chronic insomnia with objective hyperarousal 4, 1, 4, 2.